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ABSTRACT  ;  
Simple and rapid spectrophotometric method for the quantitative analysis of Pitavastatin calcium (PTV) in raw 
material and tablets pharmaceutical formulation has been described. The method is based on the formation of 
yellow ion-pair complex between Pitavastatin calcium and Bromocresol purple (BCP) in chloroform medium. 
Different parameters affecting the reaction such as: effect of solvents, stability, reagent concentration, 
correlation ratio, etc. were optimized. The formed complex was quantified spectrophotometrically at absorption 
maximum 405 nm. Linearity range was 2.20 - 35.23 µg/mL, regression analysis showed a good correlation 
coefficient R2 = 0.9991. The limit of detection (LOD) and limit of quantification (LOQ) were to be 0.367 µg/mL 
and 1.112 µg/mL respectively. The average percent recovery was found to be (100.62 – 101.14) % for Pitavastatin 
Calcium. This study was applied on Syrian pharmaceutical trademark: (PAVACRIUM 4 & Londalop). The method 
was successfully applied for the determination of Pitavastatin calcium in tablets pharmaceutical formulation. 
The proposed method is simple, direct, sensitive and do not require any extraction process. Thus, this method 
could be readily applicable for the quality control and routine analysis.  
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INTRODUCTION 
Pitavastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor which 
was discovered in Japan. It is chemically monocalcium bis (3R,5S,6E)-7-(2-cyclopropyl-4-[4-fluorophenyl]-3- 
quinolyl-3,5-dihydroxy-6-heptenoate), used as the calcium salt in the treatment of hyperlipidaemia and can 
reduce the risk of cardiovascular diseases in everyday medical practice. Based on the preclinical findings, 
Pitavastatin significantly decreased the serum levels of total cholesterol and low-density lipoprotein cholesterol 
at doses of 1 mg/day or more. It also significantly decreased the serum levels of triglycerides within this dose 
range. There was no dose-dependence of the incidence of adverse reactions to Pitavastatin. One other 
characteristic of the agent is that Pitavastatin is minimally metabolized by the cytochrome P450 isozymes; it 
undergoes glucuronidation and is converted to the inactive lactone form, therefore, the incidence of any drug 
interactions is reduced. Due to the promising results observed in clinical trials, it has the potential to be an 
excellent addition to the worldwide lipid management market1-5. 
The estimation of Pitavastatin calcium (PTV) from pharmaceutical formulations has been determining by several 
analytical methods. These include spectrophotometric method, based on ability of potassium permanganate to 
oxidize Pitavastatin in acidic medium6. UV spectrophotometric methods for the determination of Pitavastatin 
calcium7,8, Color reactions for spectrophotometric determination of Pitavastatin calcium9,10. Spectrofluorometric 
method is based on measuring the native fluorescence of the drugs at their optimum excitation and emission 
wavelengths11, High performance thin layer chromatography (HPTLC) 12,13. High performance liquid 
chromatography (HPLC)14-16. Ultra High performance liquid chromatography (UHPLC) method for the selective 
quantification of Pitavastatin calcium17. Reverse-phase high performance liquid chromatography (RP-HPLC)18-20. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS)21,22 , 
Bromocresol purple (BCP) which is a brominated acid dye of the sulfonephthalein series derived from ortho-
cresol that is obtained as a pinkish crystalline powder and is used as an acid-base indicator commonly used as 
indicator and spectrophotometric reagent. 
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MATERIALS AND METHODS 
Apparatus 
A Jasco V-630 UV–VIS spectrophotometer (Japan) with 1 cm quartz cells. Ultrasonic bath Daihan (China), and 
stirrer Velp Scientifica (Europe), Sartorius balance, sensitivity 10-5 g. 
Chemical regents: 
Pitavastatin calcium (PTV): C50H46CaF2N2O8, Mw = 880.98 g/mol from (China), its purity 99.5 %. Bromocresol 
purple (BCP): C21H16Br2O5S, MW = 540.22 g/mol from Merck (Germany). Methanol and Chloroform from Merck 
(Germany). 
STANDARD PREPARATION 
Pitavastatin calcium stock solution 
Stock solution 1×10-3 M of Pitavastatin calcium (MW = 880.98 g/mol) was prepared by dissolving 8.85 mg of 
raw material equivalent to 8.894 mg (by taken the purity in consideration) in volumetric flask 10 mL with 2 mL 
methanol and completed to volume with Chloroform to give concentration 1 × 10-3 M equivalent to 880.98 
𝜇g/mL. The working standard solutions of Pitavastatin calcium were prepared by appropriate dilutions among 
(25 - 400) 𝜇L of 880.98 𝜇g/mL solution in volumetric flasks 10 mL and added to each one of BCP 10-2 M equals 
to ten times of Pitavastatin calcium concentration, then completed to volume with Chloroform to give 
concentrations between (1.10 – 35.24) 𝜇g/mL of Pitavastatin calcium . 
Reagent stock solution 
Bromocresol purple 10-2 M was prepared by dissolving 270.11 mg of BCP (Mw = 540.22 g/mol) in volumetric 
flask 50 mL and completing to volume with Chloroform. 
Calibration Curve 
To construct the calibration curve, five standard solutions for each concentration were prepared and the 
absorbance was measured of each solution five times. 
Sample preparation 
Two products were studied : 
Twenty tablets from PAVACORIUM 4 and Londalop Syrian products were weighed and finely powdered and an 
accurate weight equivalent to 4 mg (PTV) was accurately weighed, dissolved in volumetric flask 10 mL in 
Methanol, then 1 mL of the solution was taken to volumetric flask 10 mL and diluted to volume with Chloroform. 
1 mL of the last solution was taken to volumetric flask 10 mL and added 1 mL of Bromocresol purple 10-2 M, 
then diluted to volume with Chloroform, equivalent theoretically to 4.0 𝜇g/mL for (PTV). 
RESULTS AND DISCUSSION 
Pitavastatin calcium forms with Bromocresol purple at 25 ± 5 ºC yellow ion-pair complex. The result solution 
was scanned in the range of wavelengths 300 - 550 nm against a blank of BCP solved in chloroform, then 
measured the absorbance at maximum wavelength 405 nm. We studied all the parameters of the colored result 
solutions to obtain the optimal conditions . 
Fig. 1 shows the complex spectrum between Pitavastatin calcium and Bromocresol purple in Chloroform 
medium. 
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M5 -Chloroform medium, [PTV] = 2 × 10BCP in -Spectrum of complex PTV -Fig. 1: a 
b- Spectrum of BCP in Chloroform medium, [BCP] = 2 × 10-4 M. 
Stability of stock solution 
Time effect on stability standard stock solution of Pitavastatin calcium in Chloroform was studied in three 
different concentrations 1×10-5,  2 ×10-5 and 3 × 10-5 M. We did not notice any significant absorption changes 
within one month. 
Effect of reagent concentration 
To study the effect of reagent concentration on the colored complex solution, we made a series of 10 mL of 
separated volumetric flasks, by adding 0.25 mL of Pitavastatin calcium 25 × 10-6 M equivalent to 25 µM and 
added between (0.0125 – 0.300 mL) of (BCP) 1×10-2 M, equivalent to (12.5 - 300 µM) after completing the volume 
to 10 mL by chloroform. The absorbance at 405 nm for every added (BCP) reagent was measured against the 
blank of chloroform. It was found that the completed colored complex formation in the best condition was 250 
µM of (BCP) equivalent to 0.250 mL of (BCP) which equal to ten times of Pitavastatin calcium concentration, as 
it is shown in Fig. 2. 
 
Fig. 2: Effect of reagent concentration. 
   Pitavastatin Calcium concentration 25 µM. 
Correlation ratios by molecular ratio 
We have prepared a series of complex solutions PTV-BCP in chloroform medium. The concentration of the (BCP) 
reagent changes within the ratio (0.25 × 10-4 – 7.0 × 10-5) M while the concentration of Pitavastatin calcium was 
constant in each solution and equal to 2.5 × 10-5 M. We measured the absorbance values of these solutions at 
the wavelength of the maximum absorbance 405 nm (using chloroform as a blank). The absorption changes of 
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the molecular ratio of the reagent to the Pitavastatin calcium permitted to measure correlation ratio. We 
obtained the curve A = f ([BCP]/[PTV]) shown in Fig. 3 where the correlation ratios are (1:1 & 2:1). 
 
Fig. 3: Correlation molecular ratios (1:1 & 2:1). 
Correlation ratios by continuous variation 
We have prepared a series of complex solutions PTV-BCP in the medium of the Chloroform. The concentration 
of the reagent and the concentration of Pitavastatin calcium changes in solutions between (0.5 – 5) 10-5 M where 
the sum of both concentrations remains constant and equal to 5 × 10-5 M.  
We measured the absorbance values of these solutions at the wavelength of the maximum absorbance 405 nm 
according to the used reagent percentage of the formed complex in terms of molecular fraction of Pitavastatin 
calcium. We obtained the curve A = f ([BCP] /{[BCP] + [PTV]}), shown in fig. 4, where the correlation ratios are 
also (1:1 & 2:1). 
 
Fig. 4: Correlation ratio by continuous variation (1:1 & 2:1). 
 
Calculation of formation constant for the (PTV:BCP) complex 
The conditional stability constants (𝐾𝑓) of the ion-pair complexes were calculated from molecular ratio and the 
continuous variation curves. 
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Where 𝐴 and 𝐴𝑚 are the absorbance value and the observed maximum absorbance value when all the 
Pitavastatin calcium is completely associated with Bromocresol purple, respectively. 𝐶𝑀 is the mole concentration 
of Pitavastatin calcium at the maximum absorbance and 𝑛 is the stoichiometry, which dye ion associates with 
Pitavastatin calcium. The log 𝐾𝑓 values for PTV-BCP ion-pair, associated at correlation ratio (1:1 & 2:1) by 
molecular ratio were 8.59 and 13.57 respectively, and by continuous variation were 8.66 and 13.65 respectively, 
so  log 𝐾𝑓 average are 8.63 and 13.61 at correlation ratio (1:1 & 2:1) respectively. 
METHOD’S VALIDATION 
The validity and suitability of the proposed method was assessed by linearity (evaluated by regression equation), 
limit of detection (LOD), limit of quantification (LOQ), accuracy (reported as percent %), precision (reported as 
RSD %), robustness, and Sandall's sensitivity. 
Linearity 
We studied the linearity of Pitavastatin calcium concentrations at the optimal conditions, where we made a 
series of 10 mL of separated volumetric flasks , each one contains concentration of BCP equals to ten times of 
Pitavastatin calcium concentration, where the variable concentrations of PTV stock solution 1 ×10-3 M and the 
concentrations of BCP stock solution 1 ×10-2 M, then the volumetric flasks  completed to 10 mL with Chloroform, 
finally we measured the absorbance at 405 nm for each concentration against the blank of BCP in chloroform. 
Fig. 5 presents the complex of Pitavastatin calcium with BCP spectra. The range of linearity was obeyed to Beer’s 
law in concentration (2.20 – 35.23) μg/mL and the linearity curve is presented in Fig. 6. 
  
 
        Fig. 5: spectra of (PTV-BCP) complex 
                 for different concentration of ( PTV) : 
                   C1: 4.40 𝜇g/mL, C2: 8.80 𝜇g/mL, 
                   C3: 13.21 𝜇g/mL, C4: 17.61 𝜇g/mL, 
                   C5: 22.02 𝜇g/mL, C6: 26.42 𝜇g/mL, 
                   C7: 30.83 𝜇g/mL, C8: 35.23 𝜇g/mL. 
                       n = 5 for each concentration. 
Fig. 6: Calibration curve for (PTV-BCP) complex 
     for different concentration of ( PTV) : 
             C1: 4.40 𝜇g/mL, C2: 8.80 𝜇g/mL,  
             C3: 13.21 𝜇g/mL, C4: 17.61 𝜇g/mL, 
             C5: 22.02 𝜇g/mL, C6: 26.42 𝜇g/mL, 
             C7: 30.83 𝜇g/mL, C8: 35.23 𝜇g/mL. 
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Limit of Detection (LOD) and Limit of Quantification (LOQ) 
In spite of the measurement LOD and LOQ, five concentrations were analyzed in five replicates. 
LOD and LOQ for Pitavastatin Calcium were calculated by using the following equations: 
LOD =  
3.3 ×SD
m




Where SD, is the standard deviation of y intercepts of regression lines and m is the slope of the calibration curve. 
The limit of detection (LOD) and limit of quantification (LOQ) were to be 0.367 𝜇g/mL and 1.112 𝜇g/mL 
respectively. 
Accuracy 
To determine the precision and accuracy of the proposed method, five replicates determinations were carried 
out on five different concentrations of standards (PTV). 
The validation results are presented in table 1. 



















4.40 4.41 0.097 2.20 100.23 4.41 ± 0.121 
8.80 8.85 0.151 1.71 100.57 8.85 ± 0.188 
17.61 17.47 0.097 0.56 99.20 
17.47 ± 
0.121 
26.42 27.07 0.174 0.64 102.46 
27.07 ± 
0.216 
35.23 34.69 0.074 0.21 98.47 
34.69 ± 
0.092 
: mean of five replicated determinations, Accuracy (%) = (observed concentration/theoretical concentration) 
x 100,  
Precision (RSD %) = (standard deviation/mean concentration) x 100.  
LC: Limit of confidence at 95 %; t = 2.78. 
Precision 
In order to demonstrate the precision of the proposed method, intra-day and inter-day variability studies were 
performed at three different concentrations (4.40, 13.21, and 22.02) 𝜇g/mL for Pitavastatin Calcium at the same 
day in two hour's time interval and also at three different days. Method efficiency was tested in terms of RSD % 
for both intra-day and inter-day precisions . 
The precision was ascertained by carrying out five replicates of standard Pitavastatin calcium under study and 
the mean was calculated. The results are showed in Table 2. The RSD % results were not more than 2.91 % during 
the determination in one day or three days, where the method is considered very precise. 
Table 2:  Intra-day and inter-day precision for determination of Pitavastatin calcium. 
Intra-day 
Found concentration μg/mL Concentration Sample 













I    
𝜇g/mL 
2.75 4.41 2.53 4.41 1.98 4.43 4.40 
Pitavastatin 
calcium 
0.81 13.43 1.15 13.40 1.35 13.44 13.21 
0.83 21.93 1.95 22.07 0.79 21.89 22.02 
Inter-day 








*Day II  
Precision 
RSD% 
* Day I 
2.21 4.42 2.91 4.41 2.42 4.41 4.40 
Pitavastatin 
Calcium 
0.71 13.45 0.91 13.51 1.10 13.42 13.21 
2.39 22.05 1.09 22.01 1.19 21.69 22.02 
  *n = 5. 
Robustness 
The robustness of an analytical procedure is a measure of its capacity to maintain unaffected results by a very 
small variation of some parameters and provides an indication of its reliability during normal usage. The studied 
variables parameters were slit scan speed and the wavelength, which performed at concentration (13.21 𝜇g/mL) 
for Pitavastatin calcium Table 3. 
Table 3: Robustness test. 

































 +2 nm 









  *n = 5. 
Sensitivity Sandell’s and molar absorptivity  
Sensitivity of the proposed method for Pitavastatin Calcium was determined by calculating Sandell’s sensitivity 
(SS), it was to be SS = 0.0259 µg/cm2. The mean molar absorptivity ε was found equal to 67830.11 L/mol.cm. 
Recovery 
The recovery was studied by three addition standards (80 %, 100 %, and 120 %) for every product. 
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2.54 2.57 101.00 8.04 4.00 
1.67 1.70 102.08 8.90 4.80 
101.14 





Londalop 3.21 3.23 100.50 8.02 4.00 
2.80 2.81 100.42 8.82 4.80 
 Means five separated determinations. 
APPLICATION 
Estimation of Pitavastatin Calcium in PAVACORIUM 4 and Londalop products  
The developed method was applied for quantitative determination and identification Pitavastatin Calcium in two 
Syrian pharmaceutical products (PAVACORIUM 4 and Londalop) for three different batches for each one. The 
samples were prepared as described in the section of samples preparation and analyzed. Quantitative analysis 
was done by using calibration curve. The obtained results are summarized in table 5. In general, the 
concentrations of the detected Pitavastatin Calcium compounds in the two products were within the allowed 
limits under USP legislation26 , The tablets must contain not less than 90.00 % and not more than 110.00 % of 
labeled amount. So the obtained results are conformed to USP legislation26. The relative standard deviations 
RSD % (n = 5) of the quantitative results were in the range of 0.80 – 2.90 % for PAVACORIUM 4 and 2.59 – 3.41% 
for Londalop. 
Table 5: Results of Pitavastatin Calcium in (PAVACORIUM 4 and Londalop) tablets. 
Product PAVACORIUM 4 mg/tab. 
Number of batch 1 2 3 
Concentration     
   mg/tab.    
4.001 4.030 4.101 
Range mg/tab. 4.001 – 4.101 
SD mg/tab. 0.032 0.093 0.119 
RSD % 0.80 2.31 2.90 
Range RSD % 0.80 – 2.90 
Per % 100.03 100.75 102.53 
Range Per % 100.03 – 102.53 
Product Londalop 4 mg/tab. 
Concentration 
 mg/tab. 
4.01 4.11 4.03 
Range mg/tab. 4.01 – 4.11 
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SD mg/vial 0.104 0.140 0.127 
RSD % 2.59 3.41 3.15 
Range RSD % 2.59 – 3.41 
Per % 100.25 102.75 100.75 
Range Per % 100.25 - 102.75 
 Mean for five replicates. 
CONCLUSION 
We developed a new method which is suitable for the identification and quantification of Pitavastatin Calcium 
in raw material and Syrian tablets formulation. A good percentage of recovery shows that the method can be 
successfully used in pharmaceutical quality control and routine analyses. The proposed method is simple, 
sensitive, rapid, specific, a little cost. It could be applied for quality control of Pitavastatin Calcium in 
pharmaceutical factories. The levels of Pitavastatin Calcium compounds in the analyzed preparations were found 
to be within the permissible limits set by the USP legislation26. 
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